Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
MUPIROCIN (UNII: D0GX863OA5) (MUPIROCIN - UNII:D0GX863OA5), METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E)
Sincerus Florida, LLC
TOPICAL
PRESCRIPTION DRUG
unapproved drug other
METRONIDAZOLE 1% / MUPIROCIN 2% /- METRONIDAZOLE 1% / MUPIROCIN 2% / OINTMENT SINCERUS FLORIDA, LLC _Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been_ _approved by FDA. For further information about unapproved drugs, click here._ ---------- METRONIDAZOLE 1% / MUPIROCIN 2% DIRECTIONS FOR USE SINCERUS FLORIDA, LLC. ADVERSE REACTIONS ACTIVE, INACTIVE NDC 72934- 5151-2 METRONIDAZOLE USP 1% / MUPIROCIN USP 2%, OINTMENT 30GM METRONIDAZOLE 1% / MUPIROCIN 2% / metronidazole 1% / mupirocin 2% / ointment PRODUCT INFORMATION PRODUCT T YPE HUMAN PRESCRIPTION DRUG ITE M CODE (SOURCE ) NDC:729 34-5151 ROUTE OF ADMINISTRATION TOPICAL ACTIVE INGREDIENT/ACTIVE MOIETY INGREDIENT NAME BASIS OF STRENGTH STRE NG TH MUPIRO CIN (UNII: D0 GX8 6 3OA5) (MUPIROCIN - UNII:D0 GX8 6 3OA5) MUPIROCIN 2 g in 10 0 g METRO NIDAZO LE (UNII: 140 QMO216 E) (METRONIDAZOLE - UNII:140 QMO216 E) METRONIDAZOLE 1 g in 10 0 g Sincerus Florida, LLC PACKAG ING # ITEM CODE PACKAGE DESCRIPTION MARKETING START DATE MARKETING END DATE 1 NDC:729 34-5151- 2 30 g in 1 BOTTLE, PUMP; Type 0 : No t a Co mbinatio n Pro duc t 0 5/14/20 19 MARKETING INFORMATION MARKE TING CATE GORY APPLICATION NUMBE R OR MONOGRAPH CITATION MARKE TING START DATE MARKE TING END DATE unappro ved drug o ther 0 5/14/20 19 LABELER - Sincerus Florida, LLC (080105003) ESTABLISHMENT NAME AD D RE S S ID/FEI BUSINE SS OPE RATIONS Sincerus Flo rida, LLC 0 8 0 10 50 0 3 ma nufa c ture (729 34-5151) Revised: 5/2019 Perskaitykite visą dokumentą